Boston Scientific Corp: Positive Ratings from Growth Model

Boston Scientific Corp receives a 66% rating from a respected growth model, indicating moderate interest in the stock based on its underlying fundamentals. This assessment may bolster investor confidence.

Date: 11-01-2025

AI Rating: 6

Earnings Per Share (EPS) is not mentioned in the report, thus no evaluation can be made. Revenue Growth is indirectly suggested as the stock exhibits characteristics associated with sustained future growth according to the P/B Growth Investor model. Although the details of actual revenue growth are not provided, the positive indicators could imply potential for growth. Net Income does not appear in the analysis, which limits our insight into profitability. Profit Margins (Gross, Operating, Net) are also absent from the report, so no conclusions can be drawn. Free Cash Flow (FCF) information is not present, making it hard to assess liquidity and financial health. However, the Return on Equity (ROE) is indirectly mentioned through the stock passing the criteria for Return on Assets, suggesting potentially favorable returns. The report also highlights both strengths and weaknesses in terms of financial metrics such as cash flow operational ratios and investments in research and development. Notably, while the stock passes criteria like Book/Market Ratio and Operational Cash Flow vs. Assets, it fails key tests including Advertising to Assets and Research and Development, which might raise concerns about future growth and sustainability. Overall, while the rating of 66% is positive, recent cash flow fails may present risks that could influence investor sentiment and potentially affect stock price volatility.

Stocks: BSX